Avecho Biotechnology: Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in AustraliaAvecho ...
Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Sandoz has agreed to an upfront licensing fee of US$3M (approx. A$4.8M [1]) for the exclusive commercial rights to the CBD product for insomnia in Australia. Avecho will continue to fund and oversee ...